Pascal Touchon - 16 May 2024 Form 4 Insider Report for Atara Biotherapeutics, Inc. (ATRA)

Signature
/s/ John Chao, Attorney-in-Fact for Pascal Touchon
Issuer symbol
ATRA
Transactions as of
16 May 2024
Net transactions value
-$50,289
Form type
4
Filing time
20 May 2024, 20:34:45 UTC
Previous filing
06 Mar 2024
Next filing
14 Aug 2024

Quoteable Key Fact

"Pascal Touchon filed Form 4 for Atara Biotherapeutics, Inc. (ATRA) on 20 May 2024."

Quick Takeaways

  • This page summarizes Pascal Touchon's Form 4 filing for Atara Biotherapeutics, Inc. (ATRA).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Filing timestamp: 20 May 2024, 20:34.

What Changed

  • Previous filing in this sequence was filed on 06 Mar 2024.
  • Current net transaction value: -$50,289.

Why This Matters

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Source Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATRA Common Stock Sale $50,289 -81,506 -4.3% $0.6170 1,829,146 16 May 2024 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.
F2 The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on May 16, 2024 and May 17, 2024 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .